Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
0(0%)
Results Posted
10%(1 trials)

Phase Distribution

Ph phase_4
2
15%
Ph phase_1
2
15%
Ph not_applicable
6
46%
Ph phase_3
1
8%
Ph phase_2
1
8%

Phase Distribution

2

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
2(16.7%)
Phase 2Efficacy & side effects
1(8.3%)
Phase 3Large-scale testing
1(8.3%)
Phase 4Post-market surveillance
2(16.7%)
N/ANon-phased studies
6(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.9%

10 of 11 finished

Non-Completion Rate

9.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Active(1)
Completed(10)
Terminated(1)
Other(1)

Detailed Status

Completed10
unknown1
Withdrawn1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (16.7%)
Phase 21 (8.3%)
Phase 31 (8.3%)
Phase 42 (16.7%)
N/A6 (50.0%)

Trials by Status

unknown18%
withdrawn18%
completed1077%
not_yet_recruiting18%

Recent Activity

Clinical Trials (13)

Drug Details

Intervention Type
DRUG
Total Trials
13